Valuation: Pelthos Therapeutics Inc.

Market Cap 78.87M 70.07M 65.4M 59.61M 112M 7.58B 113M 791M 307M 3.88B 296M 290M 12.44B P/E 2026 *
-1.2x
P/E 2027 * -7.32x
Enterprise Value 78.87M 70.07M 65.4M 59.61M 112M 7.58B 113M 791M 307M 3.88B 296M 290M 12.44B EV / Sales 2026 *
1.24x
EV / Sales 2027 * 0.7x
Free-Float
49.9%
Yield 2026 *
-
Yield 2027 * -
1 day+1.23%
1 week-7.17%
Current month-1.95%
1 month-17.70%
3 months-20.06%
6 months+0.98%
Current year-33.55%
1 week 20.11
Extreme 20.11
22.9
1 month 18.2
Extreme 18.205
24.99
Current year 18.19
Extreme 18.19
30.99
1 year 18.19
Extreme 18.19
37.5
3 years 4.5
Extreme 4.5
60
5 years 4.5
Extreme 4.5
60
10 years 4.5
Extreme 4.5
60
Date Insider Type Main position Quantity % Market Cap. Importance
7/2/26 A Sell

Director

-558 0.0161%
7/2/26 A Sell

Director

-786 0.0226%
7/2/26 A Sell

Chairman

-797 0.0229%
Change 5-day change 1-year change 3-year change Capi.($)
+1.23%-7.17%-22.62% - 78.87M
-0.61%-3.43%+39.40%+112.31% 1,019B
-1.02%-5.60%+37.67%+65.02% 617B
+1.11%-0.58%+11.10%+77.28% 464B
+0.34%-3.01%+61.21%+40.71% 356B
-0.95%-4.05%+21.60%+39.37% 333B
-1.46%-2.89%+11.84%+24.60% 267B
-1.35%-5.43%-4.69%+8.40% 244B
-1.04%-2.79%+35.52%+51.34% 218B
-1.87%-4.10%+30.92%+95.33% 179B
Average -0.09%-3.77%+22.19%+57.15% 369.73B
Weighted average by Cap. +0.42%-3.33%+30.52%+68.96%

Financials

2026 *2027 *
Net sales 63.75M 56.64M 52.86M 48.18M 90.87M 6.13B 91.72M 640M 248M 3.13B 239M 234M 10.05B 112M 99.71M 93.06M 84.82M 160M 10.79B 161M 1.13B 436M 5.51B 421M 412M 17.7B
Net income -62.08M -55.16M -51.48M -46.92M -88.5M -5.97B -89.32M -623M -241M -3.05B -233M -228M -9.79B -24.96M -22.17M -20.7M -18.86M -35.58M -2.4B -35.91M -250M -97.05M -1.23B -93.7M -91.66M -3.94B
Net Debt - -
Logo Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing therapeutic products for unmet patient needs. The Company's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi is a quinolone antimicrobial indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients two months of age and older. Its NaV 1.7 is a clinical-stage assets which selectively target the sodium ion-channel. The Company also Xeglyze, which is a is a pediculicide indicated for the topical treatment of head lice infestation in patients six months of age and older.
Employees
92
Date Price Change Volume
02/10/26 $20.60 +1.23% 22,028
01/10/26 $20.35 -3.14% 44,590
30/09/26 $21.01 +0.43% 5,453
29/09/26 $20.92 -1.55% 9,445
28/09/26 $21.25 -4.24% 12,007
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
20.60USD
Average target price
53.14USD
Spread / Average Target
+157.98%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTHS Stock